Bibliography
- Cancer Incidence in Five Continents (Volume VIII) . ParkinDM, WhelanSL, FerlayJ, TeppoL (Eds). IARC Scientific Publication no. 155. Lyon, France (2002).
- Jemal A , SiegelR, WardEet al. : Cancer statistics 2006.CA Cancer J. Clin.56(2), 106–130(2006).
- Feinberg AP : Cancer epigenetics takes center stage.Proc. Natl Acad. Sci. USA98(2), 392–394(2001).
- Jones PA , LairdPW: Cancer epigenetics comes of age.Nat. Genet.21(2), 163–167(1999).
- Esteller M , SparksA, ToyotaMet al. : Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer.Cancer Res.60(16), 4366–4371(2000).
- Arciero C , SomiariSB, ShriverCDet al. : Functional relationship and gene ontology classification of breast cancer biomarkers.Int. J. Biol. Markers18(4), 241–272(2003).
- Robertson JF , JaegerW, SyzmenderaJJet al. : The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. European Group for Serum Tumour Markers in Breast Cancer.Eur. J. Cancer35(1), 47–53(1999).
- Cheung KL , GravesCRL, RobertsonJF: Autoantibodies as circulating cancer markers. In: Tumor Marker: Physiology, Pathobiology, Technology, and Clinical Applications. Diamanidis EP, Fritsche HA, Lilja DW, Chan DW, Schwartz MK (Eds). AACC Press, Washington DC, USA 123–133(2002).
- Soussi T : p53 antibodies in the sera of patients with various types of cancer: a review.Cancer Res.60(7), 1777–1788(2000).
- Nicolini A , FerrariP, CavazzanaA, CarpiA, BertiP, MiccoliP: Conventional and new emerging prognostic factors in breast cancer: an update.Biomarkers Med.1(4), 525–554(2007).
- van‘t Veer LJ , PaikS, HayesDF: Gene expression profiling of breast cancer: a new tumor marker.J. Clin. Oncol.23(8), 1631–1635(2005).
- Sorlie T , PerouCM, TibshiraniRet al. : Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.Proc. Natl Acad. Sci. USA98(19), 10869–10874(2001).
- Iau PT , MacmillanRD, BlameyRW: Germ line mutations associated with breast cancer susceptibility.Eur. J. Cancer37(3), 300–321(2001).
- Seregni E , ColiA, MazzuccaN: Italian Group RIA-IRMA Test, Italian Association of Nuclear Medicine. Circulating tumour markers in breast cancer.Eur. J. Nucl. Med. Mol. Imaging31(Suppl. 1), S15–S22 (2004).
- Gion M , DaidoneMG: Circulating biomarkers from tumour bulk to tumour machinery: promises and pitfalls.Eur. J. Cancer40(17), 2613–2622(2004).
- Bast RC Jr , RavdinP, HayesDFet al.: American Society of Clinical Oncology Tumor Markers Expert Panel. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J. Clin. Oncol.19(6), 1865–1878(2001).
- Nicolini A , CarpiA, TarroG: Biomolecular markers of breast cancer.Front. Biosci.11, 1818–1843(2006).
- Nicolini A , CarpiA: β-interferon and interleukin-2 prolong more than three times the survival of 26 consecutive endocrine dependent breast cancer patients with distant metastases: an exploratory trial.Biomed. Pharmacother.59(5), 253–263(2005).
- Nicolini A , CarpiA, RossiG: Relationship of cellular immunity, cytokines and CRP with clinical course in breast cancer patients with endocrine-dependent distant metastases treated with immunotherapy.Cancer Lett.251(2), 330–338(2007).
- Nicolini A , CarpiA: Immune manipulation of advanced breast cancer: an interpretative model of the relationship between immune system and tumor cell biology.Medicinal Res. Rev. (2008) (In Press).
- Goldhirsch A , GlickJH, GelberRD, CoatesAS, ThürlimannB, SennHJ: Panel members. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.Ann. Oncol.16(10), 1569–1583(2005).
- Hayes DF , BastRC, DeschCEet al. : Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers.J. Natl Cancer Inst.88(20), 1456–1466(1996).
- Bossuyt PM , ReitsmaJB, BrunsDEet al. : Standards for reporting of diagnostic accuracy. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative.Clin. Biochem.36(1), 2–7(2003).
- Wagner JA , WilliamsSA, WebsterCJ: Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs.Clin. Pharmacol. Ther.81(1), 104–107(2007).